GlassScriptPhysician profile
Sommer Lloyd
NPI 1700476272
$3,087.52
in general payments reported to CMS, 2019-2025
37 companies · $218 in 2025
The $218 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $338 · 2022: $679 · 2023: $962 · 2024: $890 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,070.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $284.33 | 2021-2025 | Rybelsus, Ozempic |
| Sanofi-Aventis U.S. LLC | $239.17 | 2022-2024 | |
| Abbvie INC. | $217.87 | 2021-2025 | |
| Radius Health, INC. | $207.33 | 2021-2024 | Tymlos |
| Corcept Therapeutics | $159.61 | 2021-2025 | Korlym |
| Insulet Corporation | $145.51 | 2022-2025 | Omnipod |
| Alexion Pharmaceuticals, INC. | $131.38 | 2022-2024 | Strensiq |
| Amneal Pharmaceuticals LLC | $128.30 | 2022-2025 | Unithroid |
| Amgen INC. | $125.94 | 2024-2025 | Evenity, Prolia, Tepezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.82 | 2022-2025 | Synjardy, Tradjenta, Glyxambi |
| Lilly USA, LLC | $114.29 | 2022-2024 | Mounjaro, Humulin |
| Bayer Healthcare Pharmaceuticals INC. | $111.10 | 2021-2024 | |
| Cequr Corporation | $106.86 | 2023-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $105.53 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $98.11 | 2021-2023 | Gvoke Hypopen |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $80.43 | 2021-2023 | Farxiga |
| Tandem Diabetes Care, INC. | $65.77 | 2022-2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Embecta Corp. | $63.54 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Kyowa Kirin, INC. | $57.60 | 2023 | Crysvita |
| Ibsa Pharma INC. | $54.22 | 2022-2024 | Tirosint, Tirosint, Licart |
| Lifescan, INC. | $51.65 | 2021-2022 | |
| Mannkind Corporation | $44.50 | 2021-2024 | |
| Zealand Pharma US, INC. | $41.78 | 2021 | |
| Beta Bionics, INC. | $33.51 | 2024 | Ilet Bionic Pancreas |
| Recordati_rare_diseases_inc. | $33.36 | 2021-2023 | Isturisa, Signifor Lar |
| Neurocrine Biosciences, INC. | $29.41 | 2025 | |
| Becton, Dickinson and Company | $28.60 | 2022 | |
| Almatica Pharma LLC | $27.57 | 2024 | Teriparatide |
| Averitas Pharma INC. | $24.38 | 2024 | Qutenza |
| Ultragenyx Pharmaceutical INC. | $22.55 | 2023 | |
| Nevro Corp. | $22.26 | 2023 | Senza |
| Amarin Pharma, INC. | $21.97 | 2023 | |
| Antares Pharma, INC. | $20.25 | 2024 | Xyosted |
| Dexcom, INC. | $19.03 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.75 | 2024 | Evkeeza |
| Medtronic, INC. | $14.41 | 2024 | Minimed 780g |
| Tolmar, INC. | $13.83 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sommer Lloyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.